Naveen Kumar Reddy

1 month ago | opmed.doximity.com | Sachin J Shah |Naveen Kumar Reddy |Jordan Frey |Chris van Eyck

“Hope.” That’s what the 74-year-old veteran told me when he was approved to receive lecanemab, a groundbreaking new therapy for Alzheimer’s disease. “I feel like I have it again.” As a neurologist and founding member of the San Francisco VA’s Advanced Alzheimer’s Therapeutics group, I’ve found that moments like this capture both the promise and peril medical innovations bring to my patients. With the advent of these therapies, I can finally offer something essential to my patients: optimism.